找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: ;

[复制链接]
楼主: 贬损
发表于 2025-3-27 00:34:43 | 显示全部楼层
Federal Republic of Germany: Neuroleptic Relapse Preventionfrequent episodical relapses. Without neuroleptic therapy about 40%-70% of schizophrenic patients relapsed within 2 years following the first psychotic episode. In the FRG, these facts were the reason for changing from short-term neuroleptic therapy to long-term treatment. The aims of the long-term use of neuroleptics (NL) are:
发表于 2025-3-27 02:07:09 | 显示全部楼层
发表于 2025-3-27 05:25:24 | 显示全部楼层
发表于 2025-3-27 12:02:36 | 显示全部楼层
Duration of Neuroleptic Maintenance Treatmentatients are to receive this maintenance treatment (see review by Johnson, this volume) as well as the question whether reliable predictors of the individual relapse risk are available (see review by Marder, this volume). Thus a certain amount of overlap with these other reviews cannot be avoided.
发表于 2025-3-27 13:39:47 | 显示全部楼层
发表于 2025-3-27 19:30:17 | 显示全部楼层
Sweden: Neuroleptic Relapse PreventionSwedish psychiatry is sectorized. That usually means the total responsibility for all the various types of mental disorders lies within a catchment area. Within such a catchment area the in- and outpatient care is coordinated with the use of ward units as well as clinics.
发表于 2025-3-28 00:04:29 | 显示全部楼层
发表于 2025-3-28 05:37:26 | 显示全部楼层
发表于 2025-3-28 10:12:58 | 显示全部楼层
Austria: The Current Status of Maintenance Treatment in Schizophreniaut 20% of all acute hospital admissions, while the percentage of schizophrenics in long-stay units probably exceeds 30%. Twenty-nine neuroleptics of the various chemical classes are currently registered and marketed in Austria. Four of these (haloperidol, fluphenazine, flupenthixol and clopenthixol)
发表于 2025-3-28 12:45:08 | 显示全部楼层
United Kingdom: Neuroleptic Relapse Prevention(Davis 1975). Attempts to produce clear guidelines or recommendations for relapse prevention may currently be confounded by our scant knowledge regarding basic issues such as the relative value of oral and depot preparations in this regard; whether particular drugs, classes of drugs or dose regimes
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-23 22:32
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表